PFM Health Sciences LP Has $2.84 Million Stock Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

PFM Health Sciences LP decreased its position in COMPASS Pathways plc (NASDAQ:CMPS) by 58.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 451,267 shares of the company’s stock after selling 638,325 shares during the quarter. PFM Health Sciences LP’s holdings in COMPASS Pathways were worth $2,843,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Logos Global Management LP grew its stake in COMPASS Pathways by 349.3% during the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after buying an additional 901,050 shares during the last quarter. Sio Capital Management LLC boosted its holdings in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after acquiring an additional 621,222 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in COMPASS Pathways during the 3rd quarter worth approximately $2,435,000. Walleye Capital LLC acquired a new stake in COMPASS Pathways during the 3rd quarter valued at $2,126,000. Finally, Renaissance Technologies LLC raised its position in COMPASS Pathways by 1,518.4% in the 2nd quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after purchasing an additional 247,500 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CMPS. HC Wainwright decreased their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Canaccord Genuity Group dropped their target price on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Maxim Group decreased their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada dropped their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways has a consensus rating of “Buy” and an average target price of $30.67.

COMPASS Pathways Stock Performance

COMPASS Pathways stock opened at $4.60 on Friday. COMPASS Pathways plc has a 1 year low of $4.05 and a 1 year high of $12.75. The company’s 50-day moving average is $5.63 and its two-hundred day moving average is $6.57. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market cap of $314.39 million, a PE ratio of -2.09 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the business earned ($0.67) earnings per share. Equities analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

Insider Activity

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. This trade represents a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.25% of the stock is currently owned by company insiders.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.